The press release is here PTAB Denies Incyte Petition Challenging CTP-543 Patent. More importantly drug deuteration is as strong as ever with the following five victories under it's belt.
1. Auspex deuterated form of venlafaxine challenge was denied.
2. Auspex purchased by TEVA Pharmaceuticals for 3.5 billion.
3. Austedo first deuterated drug approved by FDA for Huntington's chorea.
4. Vertex purchasing CTP-656 for up to 250 million.
5. CTP-543 patent holds validity versus Incyte Corporation.
This completes the CNCE Three Hurdles To Clear, and now the company can solely focus on developing CTP-543 for Alopecia Areata, and a second soon to be announced indication. Thank you for reading.
This completes the CNCE Three Hurdles To Clear, and now the company can solely focus on developing CTP-543 for Alopecia Areata, and a second soon to be announced indication. Thank you for reading.
No comments:
Post a Comment